Objectively measure speech in Parkinson’s disease patients with great precision

In 2020, an estimated 9.4 million people globally were living with Parkinson’s disease, with numbers increasing to 12.7 million people by 2027. Coupled with the subjective nature of current Parkinson’s disease monitoring assessment methods, there is a need for sensitive, scalable and meaningful assessments of disease monitoring. Redenlab is a world leader in the development of speech data capture and analysis tools, creating objective motor speech and cognitive-linguistic-based assessments. Their approach has proven utility in industry and academic driven studies, enhancing decision making at each stage of the drug development and evaluation process.

ParkinSong: a clinical trial turn PD treatment

Working with scientists from the Conservatorium of Music at The University of Melbourne in Australia, Redenlab assisted in outcome measure design and analysis for a randomized trial of ParkinSong, a group therapy session for people with Parkinson’s disease.

Since its clinical trial, the therapy has been employed across Australia by Parkinson’s Australia, an Australian advocacy group dedicated to improving the quality of life of people diagnosed with Parkinson’s disease.

Redenlab Parkinson’s Disease experience








Clinical trials



Natural history studies


    While speech biomarkers of disease have attracted increased interest in recent years, a challenge is that features derived from signal...
      Face to face singing therapy can improve speech in PD. Have a look at our previous work published in Neurorehabilitation...

      Latest news and updates

      • Posted on 17 June, 2024
        Up to half of all people with multiple sclerosis experience communication difficulties due to dysarthria, a disorder that impacts the motor aspects of speech production. Dysarthria in multiple sclerosis is linked to cerebellar dysfunction, disease...
        • Posted on 12 June, 2024
          Frontotemporal Dementia (FTD) encompasses a range of progressive neurodegenerative conditions that impair speech production and comprehension, higher cognitive functions, behavior, and motor skills. Considerable research has focused on conventional acoustic speech markers in FTD, as...